title: [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
abstract: OBJECTIVE
  To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen.
  
  
  METHODS
  Clinical data of 21 patients with MDS-RAEB or refractory AML from July 2011 to July 2014 were analyzed retrospectively. Among 21 patients there were 4 cases of MDS-RAEB and 17 cases of refractory AML; 12 cases were beyond 60 years old; 13 cases had high-risk karyotypes. All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19.
  
  
  RESULTS
  After 1 cycle of treatment with DCAG regimen, the outcome of 21 patients showed that 8 cases achieved complete remission (42.1%), 8 cases achieved partial remission (42.1%), 2 cases achieved hematologic improvement, 1 cases achieved non-remission and 2 cases died; and the 1 year overall survival rate was 67.5%. The outcome of 12 patients beyond 60 years old showed that 6 cases achieved complete renission (60%, 6/10), and the 1 year overall survival rate was 62.5%. The outcome of 13 patients with high-risk karytype showed that 6 cases achieved complete renission (54.5%, 6/11), and the 1 year overall survival rate was 61.5%. The main adverse event was myelosuppression, and non-hematological toxicity included liver dysfunction and gastrointestinal tract reaction.
  
  
  CONCLUSIONS
  Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases.
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Xue-Liang
authors: XL
authors: Yang
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Ya-Mei
authors: YM
authors: Wu
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Yong-Bin
authors: YB
authors: Cao
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Xiao-Hong
authors: XH
authors: Li
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Li-Xin
authors: LX
authors: Xu
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Zhou-Yang
authors: ZY
authors: Liu
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Bei
authors: B
authors: Liu
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Bei
authors: B
authors: Yan
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China.
authors: Song-Wei
authors: SW
authors: Li
authors: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors: Wan-Ming
authors: WM
authors: DA
authors: Department of Hematology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China. E-mail: xiongwuxiao@sohu.com.
authors: Xiao-Xiong
authors: XX
authors: Wu
mesh_terms: D015250:Aclarubicin / Q000031:analogs & derivatives; D000971:Antineoplastic Combined Chemotherapy Protocols; D001374:Azacitidine / Q000031:analogs & derivatives; D003561:Cytarabine; D000077209:Decitabine; D016179:Granulocyte Colony-Stimulating Factor; D006801:Humans; D059785:Karyotype; D015470:Leukemia, Myeloid, Acute; D009190:Myelodysplastic Syndromes; D010198:Pancytopenia; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C011157:aclacinomycins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin; D000077209:Decitabine; D001374:Azacitidine